Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

PURPOSE: We conducted the first phase 0 clinical trial in oncology of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US Food and Drug Administration. It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in patients with advanc...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Kummar, Shivaani, Kinders, Robert, Gutierrez, Martin E., Rubinstein, Larry, Parchment, Ralph E., Phillips, Lawrence R., Ji, Jiuping, Monks, Anne, Low, Jennifer A., Chen, Alice, Murgo, Anthony J., Collins, Jerry, Steinberg, Seth M., Eliopoulos, Helen, Giranda, Vincent L., Gordon, Gary, Helman, Lee, Wiltrout, Robert, Tomaszewski, Joseph E., Doroshow, James H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2009
Soggetti:
Original Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2739635/
https://ncbi.nlm.nih.gov/pubmed/19364967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.19.7681
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi